scispace - formally typeset
J

Jinfeng Li

Researcher at Zhengzhou University

Publications -  6
Citations -  430

Jinfeng Li is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Apoptosis & Cytotoxicity. The author has an hindex of 5, co-authored 6 publications receiving 340 citations.

Papers
More filters
Journal ArticleDOI

Triazole–Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration

TL;DR: Five series of 1,2,3-triazole-dithiocarbamate hybrids were designed and synthesized and screened their inhibitory activity toward LSD1 and it was found that some of these compounds exhibited the most specific and robust inhibition of LSD1.
Journal ArticleDOI

A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.

TL;DR: A review of recent studies about LSD1 focuses on the basic physiological function of LSD1 and its involved mechanisms in pathophysiologic conditions, as well as the development of LSD 1 inhibitors as potential anticancer therapeutic agents.
Journal ArticleDOI

SP600125 enhances C-2-induced cell death by the switch from autophagy to apoptosis in bladder cancer cells

TL;DR: A series of molecular mechanisms about SP600125 potentiate the cytotoxicity and tumor inhibition of C-2 in bladder cancer cells through promoting C- 2-induced apoptosis is revealed, expecting it provides research basis and theoretical support for new drugs development.
Journal ArticleDOI

A new brominated chalcone derivative suppresses the growth of gastric cancer cells in vitro and in vivo involving ROS mediated up-regulation of DR5 and 4 expression and apoptosis.

TL;DR: Intraperitoneal administration of H72 significantly inhibited the growth of MGC803 cells in vivo in a xenograft mouse model without observed toxicity indicated that H72 is a lead brominated chalcone derivate and deserves further investigation for prevention and treatment of gastric cancer.
Journal ArticleDOI

1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors

TL;DR: Findings indicate that compound 3a is a potent, reversible and cell active SIRT1 inhibitor and deserves further investigation as an anticancer agent or a biological tool.